Mike Wajnrajch is a pediatric endocrinologist and has been the US Medical Director for Elelyso since Dec 2011 and has been at Pfizer for over 10 years. Prior to joining Pfizer, Dr Wajnrajch was an Associate Professor of Pediatrics at Cornell University Medical Center.
Dr Wajnrajch lived in Israel for 3 ½ years, and graduated from the Technion Israel Institute of Technology, and has been caring for patients as well as been involved in research in rare diseases for over 20 years, ranging from clinical research to molecular genetics.
As the US Medical Director, Dr Wajnrajch coordinates US medical programs with the Israeli Biotech, Protalix, the developers of a novel plant cell-based technology and Elelyso, an enzyme replacement therapy for adults with type 1 Gaucher disease. Gaucher disease is the most common of the 19 Genetic Diseases that can be identified in the “Screen for 19 program”.
Along with his work at Pfizer, Dr Wajnrajch continues his clinical care responsibilities (at NYU), continues his work with Patient Advocacy groups and efforts to increase awareness and screening for Genetic Diseases among high-risk groups, including Ashkenazi Jews.